Sensei Biotherapeutics, Inc. Common Stock
SNSE—US Equity
$13.85▼ $3.97 (−22.28%)
Latest quoteTrack SNSE
Get earnings, price moves & breaking news on Telegram
24h▼ 22.3%
7d—
14d—
30d—
ytd—
1y—
🏦Market Cap
—
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
—
Otter Score
—
Insufficient data
No chart data available for SNSE.
Trading Snapshot
- Day Range
- $13.76 – $16.52
- 52-Week Range
- —
- Volume (shares)
- 219,467
- Avg Volume (shares)
- —
- Shares Outstanding
- —
- Next Earnings
- —
Fundamentals Snapshot
- Annual Revenue
- —
- Last Q Revenue
- —
- P/E Ratio
- —
- P/S Ratio
- —
- EPS (TTM)
- —
- Dividend Yield
- —
- Dilution (1yr)
- −95.0%
Sensei Biotherapeutics, Inc. Common Stock
SNSEFinancial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$22M▼ −29.6% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$20M▼ −17.5% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
1.3M▼ −95.0% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$7M▲ +$1M YoY
StockOtter · stockotter.spaceAbout Sensei Biotherapeutics, Inc. Common Stock
A company profile for Sensei Biotherapeutics, Inc. Common Stock isn’t available yet — check back soon.
🦦
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
💧Dilution★★★★★
Overall Score
Insufficient data
—/100
Analyst data unavailable.
Latest News & Updates
News unavailable.